NCT03175120 - A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | Biotech Hunter

Enrollment

453

Participants

Timeline

Start Date

May 26, 2017

Primary Completion Date

March 5, 2019

Study Completion Date

April 4, 2019

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

Insulin degludec/liraglutide

Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

DRUG

Insulin degludec

Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

Trial Locations (37)

100071

Novo Nordisk Investigational Site, Beijing

100088

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

100853

Novo Nordisk Investigational Site, Beijing

116011

Novo Nordisk Investigational Site, Dalian

130021

Novo Nordisk Investigational Site, Changchun

130033

Novo Nordisk Investigational Site, Changchun

136000

Novo Nordisk Investigational Site, Siping

150001

Novo Nordisk Investigational Site, Harbin

200040

Novo Nordisk Investigational Site, Shanghai

200072

Novo Nordisk Investigational Site, Shanghai

200240

Novo Nordisk Investigational Site, Shanghai

201199

Novo Nordisk Investigational Site, Shanghai

210011

Novo Nordisk Investigational Site, Nanjing

210012

Novo Nordisk Investigational Site, Nanjing

210029

Novo Nordisk Investigational Site, Nanjing

212001

Novo Nordisk Investigational Site, Zhenjiang

213003

Novo Nordisk Investigational Site, Changzhou

230001

Novo Nordisk Investigational Site, Hefei

230061

Novo Nordisk Investigational Site, Hefei

300052

Novo Nordisk Investigational Site, Tianjin

330006

Novo Nordisk Investigational Site, Nanchang

350001

Novo Nordisk Investigational Site, Fuzhou

404000

Novo Nordisk Investigational Site, Chongqing

414000

Novo Nordisk Investigational Site, Yueyang

510120

Novo Nordisk Investigational Site, Guangzhou

510515

Novo Nordisk Investigational Site, Guangzhou

650101

Novo Nordisk Investigational Site, Kunming

710061

Novo Nordisk Investigational Site, Xi'an

750004

Novo Nordisk Investigational Site, Yinchuan

053000

Novo Nordisk Investigational Site, Hengshui

050000

Novo Nordisk Investigational Site, Shijiazhuang

063000

Novo Nordisk Investigational Site, Tangshan

010020

Novo Nordisk Investigational Site, Hohhot

010050

Novo Nordisk Investigational Site, Hohhot

030001

Novo Nordisk Investigational Site, Taiyuan

Unknown

Novo Nordisk Investigational Site, Shatin, New Territories